The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan. (2017)
Attributed to:
A randomised placebo-controlled study examining the role of anti-IgE in severe recalcitrant paediatric atopic eczema
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s13063-017-1976-6
PubMed Identifier: 28535776
Publication URI: http://europepmc.org/abstract/MED/28535776
Type: Journal Article/Review
Volume: 18
Parent Publication: Trials
Issue: 1
ISSN: 1745-6215